Morphological characterisation of portal myofibroblasts and hepatic stellate cells in the normal dog liver
© IJzer et al; licensee BioMed Central Ltd. 2006
Received: 04 July 2005
Accepted: 16 November 2006
Published: 16 November 2006
Hepatic fibrosis is a common outcome of hepatic injury in both man and dog. Activated fibroblasts which develop myofibroblastic characteristics play an essential role in hepatic fibrogenesis, and are comprised of three subpopulations: 1) portal or septal myofibroblasts, 2) interface myofibroblasts and 3) the perisinusoidally located hepatic stellate cells (HSC). The present study was performed to investigate the immunohistochemical characteristics of canine portal myofibroblasts (MF) and HSC in the normal unaffected liver as a basis for further studies on fibrogenesis in canine liver disease.
In the formalin-fixed and paraffin embedded normal canine liver vimentin showed staining of hepatic fibroblasts, probably including MF in portal areas and around hepatic veins; however, HSC were in general negative. Desmin proved to react with both portal MF and HSC. A unique feature of these HSC was the positive immunostaining for alpha-smooth muscle actin (α-SMA) and muscle-specific actin clone HHF35 (HHF35), also portal MF stained positive with these antibodies. Synaptophysin and glial fibrillary acidic protein (GFAP) were consistently negative in the normal canine liver. In a frozen chronic hepatitis case (with expected activated hepatic MF and HSC), HSC were negative to synaptophysin, GFAP and NCAM. Transmission electron microscopy (TEM) immunogold labelling for α-SMA and HHF35 recognized the positive cells as HSC situated in the space of Disse.
In the normal formalin-fixed and paraffin embedded canine liver hepatic portal MF and HSC can be identified by α-SMA, HHF35 and to a lesser extent desmin immunostaining. These antibodies can thus be used in further studies on hepatic fibrosis. Synaptophysin, GFAP and NCAM do not seem suitable for marking of canine HSC. The positivity of HSC for α-SMA and HHF35 in the normal canine liver may eventually reflect a more active regulation of hepatic sinusoidal flow by these HSC compared to other species.
Hepatic fibrosis is a common outcome of hepatic injury in both man and dog. Depending on the primary site of injury the fibrosis may be restricted to the portal areas as in most biliary diseases or may be present in the hepatic parenchyma as seen in chronic hepatitis and cirrhosis. Chronic hepatitis is often diagnosed in pet-dogs. Treatment provides only limited results and the underlying mechanism of fibrosis is unclear. Activated fibroblasts which develop myofibroblasts (MF) characteristics play an essential role in hepatic fibrogenesis . Three different MF-like cells have been described in rat and man based on location and immunohistochemical profile [2–4]. These comprise 1) portal or septal MF, present in the portal areas or in newly formed fibrous septa, 2) interface MF, present at the interface between parenchyma and stroma of the portal areas or newly formed fibrous septa, and 3) the perisinusoidally located hepatic stellate cells (HSC), also known as vitamin A-storing HSC, Ito-cells, hepatic lipocytes, lipid-laden cells, fat-storing cells or perisinusoidal lining cells. Debate exists regarding the origin of portal and interface MF and HSC. They may have a common origin in the primitive mesenchyme of the embryonal septum transversum. It remains to be elucidated which circumstances then lead to a different phenotype for the portal and interface MF and the HSC [5, 6]. If stromal environment may promote transition and differentiation of HSC towards stromal MF, this might have therapeutic implications in patients.
Although portal and interface MF have been considered to have fibrogenic potential [7, 8], most investigators regard the HSC as the principal fibrocompetent cell in the liver [5, 9, 10]. HSC are located in Disse's space, in between the hepatocytes and the sinusoidal endothelium, and play an important role in normal and diseased liver as they 1) produce the extracellular matrix, 2) act in a pericyte like manner around the sinusoids thus regulating sinusoidal blood flow, and 3) are the major site of vitamin-A storage in lipid vacuoles [9, 10].
HSC have species-specific immunohistochemical expression profiles. All HSC express vimentin (rat), desmin (rat) and actin (man and rat), but alpha-smooth muscle actin (α-SMA) is classically considered as an indicator of activation (man and rat) [6, 9, 11]. However, in man α-SMA HSC reactivity proved to be strongly dependent on immunostaining conditions . In addition to these myofibroblastic markers, human HSC also display some neuroendocrine features distinguishing them from the other hepatic MF-like cells in fibrotic liver . They express synaptophysin , nerve growth factor (NGF), brain derived nerve growth factor (BDNF), neurotrophin-3 (NT-3), NT-receptors tyrosine kinase (Trk)-B and -C, and low-affinity nerve growth receptor p-75 (Trk-A), while other neuroendocrine markers as neural cell adhesion molecule (NCAM), glial fibrillary acidic protein (GFAP), NT-4, and alpha B-crystallin are expressed to a much higher extent in HSC than in the other hepatic MF subpopulations . With parenchymal injury HSC transfer from a quiescent phenotype into an activated or transdifferentiated state characterised by increased proliferation, contractility and migration, as well as loss of vitamin-A containing lipid vacuoles and enhanced expression of α-SMA and desmin [9, 11, 14–16]. Furthermore, HSC produce growth factors as hepatocyte growth factor (HGF), transforming growth factor beta (TGF-β) as well as matrix metalloproteinases and abundant amounts of extracellular matrix components including collagen, proteoglycans and adhesive glycoprotein [5, 9, 16–18]. In dogs portal and interface MF and HSC have only been studied with α-SMA in activated HSC in a CCl4 intoxication model .
The purpose of this study was to investigate immunohistochemical characteristics of canine portal and interface MF and HSC in the normal unaffected liver, as a basis for further studies on fibrosis in canine liver disease.
Routine haematoxylin and eosin (H&E) sections in all dogs revealed a normal liver. With large individual differences, presumptive vitamin A-storing HSC were regularly seen with a single large vacuole (vitamin A-storing lipid droplet) and a dislocated nucleus. HSC without a vitamin A-storing vacuole ("empty HSC") could not be identified on H&E sections. In immunostaining, negative controls were negative.
Muscle-specific actin clone HHF35 (HHF35)
GFAP, synaptophysin and NCAM
In formalin fixed normal canine liver tissue GFAP staining revealed few positive nerves located in larger portal areas (internal positive control) but no other positive staining was observed in any other location in these sections. Despite strong staining for synaptophysin in the adrenal medulla (external positive control), no staining was observed in any of the formalin fixed normal liver sections. In the frozen chronic hepatitis case (with expected activated hepatic MF and HSC), only nerves in larger portal areas reacted positively to GFAP and NCAM, while synaptophysin did not provoke any signal at all.
Immunogold ultrastructural localization
No antibody used in this study is species specific for the dog, but they still can be used due to interspecies cross-reactivity. All antibodies have been used previously in multiple other canine studies [20–26].
Variation in vimentin and desmin staining pattern was widely present. This might be due to the varying epitope sensibility, caused by the intrinsic patient material variability regarding time of postmortal sampling and fixation, the age of the paraffin blocks, and age, sex and breed variation of the animals. However, the used material reflects similar variability in intended patient populations to be studied for spontaneously occurring hepatic fibrosis, and thus provides useful insight in normal baseline variation.
In the formalin fixed paraffin embedded normal canine liver vimentin staining did not differentiate between fibroblasts and MF in the portal area and the perivenous stromal tissue. Moreover, HSC stained generally negative. Therefore, we conclude that vimentin antibody is not useful in paraffin sections as a marker for canine portal MF or HSC. Desmin stained MF in the portal area, around the sublobular hepatic vein and in Glisson's capsule. HSC stained inconsistently, with large variation between slides, so we conclude that desmin is not a sensitive marker for canine HSC. This is in contrast to man , but in accordance to rat .
In our laboratory, both α-SMA and HHF35 do identify myoepithelial cells in canine mammary gland. These monoclonal antibodies recognise different epitopes: a NH2 terminal decapeptide (α-SMA), and α and γ muscle actin (HHF35). The chance of formalin-induced epitope masking was regarded smaller by use of two different monoclonal antibodies for the same peptide. Therefore, both markers were investigated in related (regarding possible contractility) cells in the liver, being HSC and portal MF. In formalin fixed paraffin sections these cells can be easily identified in the normal canine liver by immunohistochemical staining for both α-SMA and HHF35. Both antibodies produced almost identical results and stained both solitary MF in the portal areas as well as HSC in the hepatic parenchyma. The presence of small lipid vacuoles in positively staining perisinusoidal cells as well as the TEM immunohistochemical results confirms the nature of the latter cells as HSC. The vitamin A-storing HSC usually stained positive for α-SMA but reacted only rarely to HHF35, suggesting differentiation in staining characteristics between less contractile vitamin A-storing HSC and more contractile HSC. The present finding of α-SMA reactivity which was diffusely present throughout the hepatic parenchyma in the normal canine liver is in contrast with findings in normal human and rat liver, where the majority of hepatic lobules are devoid of α-SMA positive HSC, or only show weak positivity [2, 6, 9, 12]. In our opinion, this indicates a species-specific expression pattern for the dog. Rat and human HSC upregulate α-SMA expression upon activation [2, 6, 28] and this positive staining of activated HSC is considered to represent increased contractility of the cells [29, 30].
Debate still exists regarding the contribution of non-activated quiescent HSC to sinusoidal blood flow and blood pressure in man and rat [9, 11]. Our findings of α-SMA staining in HSC of normal dogs may suggest a more active role in controlling microvascular blood flow compared to the rat. Interestingly, the dog is unique in that it has a spirally shaped smooth muscle surrounding the sublobular hepatic veins consistent with a more active regulation of the hepatic blood flow in the dog compared to other species .
Despite positive staining of HSC for α-SMA in normal dogs reflecting contractility we feel it appropriate to regard these cells as "quiescent" HSC. This is in line with other species as HSC are most likely not activated in the sense of enhanced matrix- or TGF-β production. In the dog discrimination between quiescent and activated HSC does not seem possible with antibodies directed against α-SMA and HHF35. However, morphological changes or functional changes such as increased cell size, loss of lipid vacuoles and enhanced production of TGF-β and other substances may be helpful.
The absence of reactivity of portal MF and HSC in the normal canine liver to synaptophysin and GFAP indicates that in contrast to man and rat [2, 3, 6], canine portal MF and HSC do not seem to express the used markers in the normal liver. Moreover, in frozen sections from a dog with chronic active hepatitis which likely contained activated MF and HSC, these cells did also not react to antibodies for neural crest markers NCAM, GFAP and synaptophysin. As in frozen samples antigens retrieval is not necessary, we conclude that not only in the quiescent state but also in the activated state, canine portal MF and HSC do not bind the used antibodies for NCAM, GFAP and synaptophysin. Although probably limited by species-specificity of the antibodies, this study could be expanded by the use of more frozen tissue samples, or by the use of other potential markers, reacting positively on hepatic MF in other species, like NGF, BDNF, NT-3, NCAM , Foxf1  or fibulin-2 .
In formalin fixed paraffin sections, canine portal MF and HSC can be identified by α-SMA, HHF35 and to a lesser extent desmin immunostaining. In contrast to man, these cells are consistently negative for synaptophysin, GFAP and NCAM, both in formalin-fixed paraffin embedded tissue, as well as in frozen sections. Alpha-SMA and HHF35 positivity of HSC in the normal canine liver may reflect a more active regulation of hepatic sinusoidal flow by these cells compared to other species. Alpha-SMA and HHF35 can be used for further studies on hepatic fibrosis in the dog.
Materials and methods
Normal liver tissue was obtained from ten dogs for immunohistochemistry: either patients with liver unrelated pathology (n = 8) or normal control animals euthanized for liver-unrelated research projects (n = 2). Laboratory exams regarding liver function were not performed. One frozen sample of a dog with chronic hepatitis was additionally used. Patients were submitted for their individual diagnostic purposes to the Department of Clinical Sciences of Companion Animals, or to the Department of Pathology, Faculty of Veterinary Medicine, Utrecht University. No tissue was taken purposely for the reported study. Projects were approved by the responsible ethical committees for the use of experimental animals and for use of client-owned animals according to Dutch legislation. After euthanasia as part of the research projects, we were allowed to take liver tissue of the two control animals. Included were six females and four males. Mean age was 13 months (± 15 months).
Details concerning the used antibodies.
Immunogold ultrastructural localization
For TEM, additional liver samples were taken from two female dogs, three and seven years old. Both were normal control animals euthanized for liver-unrelated research projects. Projects were approved by the responsible ethical committees for the use of experimental animals as required under Dutch legislation. After euthanasia as part of the projects, we were allowed to take liver tissue. Liver samples were taken immediately postmortem, fixed in 4% paraformaldehyde for 2 days, subsequently washed and transferred in methanol to an auto freezing device from Reichert. Freeze substitution was performed 36 h at -85°C in methanol, temperature was gradually raised in 5°C-steps to -45°C, followed by serial substitution from methanol to Lowicryl HM20 from methanol:HM20 = 2:1 (2 × 1 h) to methanol:HM20 = 1:2 (2 × 1 h) and pure HM20 2 h at -45°C. Polymerisation was performed for 36 h at -45°C, then temperature was raised in 5°C-steps for 13 h up to 20°C. Temperature stayed 20°C for 150 h all under UV-light. After ultrathin sectioning grids were labelled according to the procedure for single labelling. Free aldehyde groups were blocked in 50 mM glycine in PBS for 15 min, followed by 30 min aurion blocking solution for goat gold conjugates and washed in BSA-c buffer (PBS + 0.1% BSA-c, pH 7.4), 3 × 5 min. Overnight incubation of the primary antibodies α-SMA and HHF35 diluted in BSA-c buffer (1:1200 and 1:300 respectively) was followed by BSA-c buffer wash (6 × 5 min) and incubation of goat-anti-mouse IgG ultra small gold diluted 1:50 in BSA-c buffer (2 h). BSA-c buffer wash (6 × 5 min) and PBS wash (3 × 5 min) was done previous to postfixation in 2% glutaraldehyde in PBS (5 min), followed by wash in PBS (5 min) and distilled water (5 × 2 min). Signal enhancement was done using Aurion R-Gent SE-EM (30 min), and subsequent washing in distilled water (5 × 2 min). Grids were then stained with uranyl acetate and lead citrate. For sample evaluation a Philips CM 10 TEM was used.
We thank Paula Aertsen for her technical support.
- Crawford JM: Liver cirrhosis. Pathology of the Liver. Edited by: MacSween RNM, Burt AD, Portmann BC, Ishak KG, Scheuer PJ, Anthony PP. 2002, Edinburgh: Churchill Livingstone, 575-619.Google Scholar
- Cassiman D, Libbrecht L, Desmet V, Denef C, Roskams T: Hepatic stellate cell/myofibroblast subpopulations in fibrotic human and rat livers. J Hepatol. 2002, 36: 200-209. 10.1016/S0168-8278(01)00260-4.View ArticlePubMedGoogle Scholar
- Knittel T, Kobold D, Piscaglia F, Saile B, Neubauer K, Mehde M, Timpl R, Ramadori G: Localization of liver myofibroblasts and hepatic stellate cells in normal and diseases rat livers: distinct roles of (myo-)fibroblast subpopulations in hepatic tissue repair. Histochem Cell Biol. 1999, 112: 387-401. 10.1007/s004180050421.View ArticlePubMedGoogle Scholar
- Guyot C, Lepreux S, Combe C, Doudnikoff E, Bioulac-Sage P, Balabaud C, Desmouliere A: Hepatic fibrosis and cirrhosis: The (myo)fibroblastic cell subpopulations involved. Int J Bioch & Cell Biol. 2006, 38: 135-151.Google Scholar
- Ramadori G, Saile B: Mini Review Portal tract fibrogenesis in the liver. Lab Invest. 2004, 84: 153-159. 10.1038/labinvest.3700030.View ArticlePubMedGoogle Scholar
- Roskams T, Cassiman D, de Vos R, Libbrecht L: Neuroregulation of the neuroendocrine compartment of the liver. Anat Rec A Discov Mol Cell Evol Biol. 2004, 280A: 910-923. 10.1002/ar.a.20096.View ArticleGoogle Scholar
- Bhunchet E, Wake K: Role of mesenchymal cell populations in porcine serum-induced rat liver fibrosis. Hepatology. 1992, 16: 1452-1473.View ArticlePubMedGoogle Scholar
- Tuchweber B, Desmouliere A, Bochaton-Piallat L, Rubbia-Brandt L, Gabbiani G: Proliferation and phenotypic modulation of portal fibroblasts in the early stages of cholestatic fibrosis in the rat. Lab Invest. 1996, 74: 265-278.PubMedGoogle Scholar
- Bedossa P, Paradis V: Review article Liver extracellular matrix in health and disease. Journal of Pathology. 2003, 200: 504-515. 10.1002/path.1397.View ArticlePubMedGoogle Scholar
- MacSween RNM, Desmet VJ, Roskams T, Scothorne RJ: Developmental anatomy and normal structure. Pathology of the Liver. Edited by: MacSween RNM, Burt AD, Portmann BC, Ishak KG, Scheuer PJ, Anthony PP. 2002, Edinburgh: Churchill Livingstone, 1-66.Google Scholar
- Burt AD: Review Pathobiology of hepatic stellate cells. J Gastroenterol. 1999, 34: 299-304. 10.1007/s005350050264.View ArticlePubMedGoogle Scholar
- Lepreux S, Dubuisson L, Lebail B, Desmouliere A, Balabaud C, Bioulac-Sage P: Can hepatic stellate cells express alpha-smooth muscle actin in normal human liver?. Liver. 2001, 21: 293-294. 10.1034/j.1600-0676.2001.021004293.x.View ArticlePubMedGoogle Scholar
- Cassiman D, van Pelt J, de Vos R, van Lommel F, Desmet V, Yap S-H, Roskams T: Synaptophysin: a novel marker for human and rat hepatic stellate cells. Am J Pathol. 1999, 155: 1831-1839.PubMed CentralView ArticlePubMedGoogle Scholar
- Safadi R, Friedman SL: Hepatic fibrosis-role of stellate cell activation. Med Gen Med. 2002, 4: 27-10.1002/jgm.242.View ArticleGoogle Scholar
- Reeves HL, Friedman SL: Activation of hepatic stellate cells – a key issue in liver fibrosis. Front Biosci. 2002, 7: 808-826.View ArticleGoogle Scholar
- Sato M, Suzuki S, Senoo H: Review Hepatic stellate cells: unique characteristics in cell biology and phenotype. Cell Struct Funct. 2003, 28: 105-112. 10.1247/csf.28.105.View ArticlePubMedGoogle Scholar
- Senoo H: Structure and function of hepatic stellate cells. Med Electron Microsc. 2004, 37: 3-15. 10.1007/s00795-003-0230-3.View ArticlePubMedGoogle Scholar
- Bataller R, Brenner DA: Liver fibrosis. J Clin Invest. 2005, 115: 209-218. 10.1172/JCI200524282.PubMed CentralView ArticlePubMedGoogle Scholar
- Zhang RP, Zhang WH, Xue DB, Wei YW: Morphology of portal hypertension at the early stage of liver damage induced by CCl4: an experimental study with dogs. Zhonghua Yi Xue Za Zhi. 2004, 84: 1118-1121.PubMedGoogle Scholar
- Barnhart KF, Wojcieszyn J, Storts RW: Immunohistochemical staining patterns of canine meningiomas and correlation with published immunophenotypes. Vet Pathol. 2002, 39: 311-321. 10.1354/vp.39-3-311.View ArticlePubMedGoogle Scholar
- Mukaratirwa S, de Witte E, van Ederen AM, Nederbragt H: Tenascin expression in relation to stromal tumour cells in canine gastrointestinal epithelial tumours. J Comp Pathol. 2003, 129: 137-146. 10.1016/S0021-9975(03)00021-5.View ArticlePubMedGoogle Scholar
- Ramos-Vara JA, Beissenherz ME: Optimization of immunohistochemical methods using two different antigen retrieval methods on formalin-fixed, paraffin-embedded tissues; experience with 63 markers. J Vet Diagn Invest. 2000, 12: 307-311.View ArticlePubMedGoogle Scholar
- Sako T, Shimoyama Y, Akihara Y, Ohmachi T, Yamashita K, Kadosawa T, Nakade T, Uchida E, Okamot M, Hirayama K, Taniyama H: Neuroendocrine carcinoma in the nasal cavity of ten dogs. J Comp Pathol. 2005, 133: 155-163. 10.1016/j.jcpa.2005.04.002.View ArticlePubMedGoogle Scholar
- Vos JH, van den Ingh TS, de neijs M, van Mil FN, Ivanyi D, Ramaekers FC: The expression of keratins, vimentin, neurofilament proteins, smooth muscla actin, neuron-specific enolase, and synaptophysin in tumors of the specific glands in the canine anal region. Vet Pathol. 1993, 30: 352-61.View ArticlePubMedGoogle Scholar
- Vos JH, van den Ingh TS, de neijs M, van Mil FN, Ivanyi D, Ramaekers FC: Immunohistochemistry with keratin and smooth muscle actin monoclonal antibodies in canine digestive tract and extramural glands. Zentralbl Veterinarmed A. 1992, 39: 241-257.View ArticlePubMedGoogle Scholar
- Perez J, Bautista MJ, Rollon E, de Lara FC, Carrasco L, Martin de las Mulas J: Immunohistochemical characterization of hemangiopericytomas and other spindle cell tumors in the dog. Vet Path. 1996, 33: 391-7.View ArticleGoogle Scholar
- Burt AD, Robertson JL, Heir J, MacSween RN: Desmin-containing stellate cells in rat liver; distribution in normal animals and response to experimental acute liver injury. J Pathol. 1986, 150: 29-35. 10.1002/path.1711500106.View ArticlePubMedGoogle Scholar
- Hautekeete ML, Geerts A: The hepatic stellate (Ito) cell: its role in human liver disease. Virch Arch. 1997, 430: 195-207. 10.1007/BF01324802.View ArticleGoogle Scholar
- Rockey DC: The cellular pathogenesis of portal hypertension: stellate cell contractility, endothelin and nitric oxide. Hepatology. 1997, 25: 2-5. 10.1002/hep.510250102.View ArticlePubMedGoogle Scholar
- Rockey D, Weisiger R: Endothelin induced contractility of stellate cells from normal and cirrhotic rat liver: implications for regulation of portal pressure and resistance. Hepatology. 1996, 24: 233-240. 10.1002/hep.510240137.View ArticlePubMedGoogle Scholar
- Yamamoto K: Ultrastructural study on the venous sphincter in the sublobular vein of the canine liver. Microvasc Res. 1998, 55: 215-222. 10.1006/mvre.1998.2080.View ArticlePubMedGoogle Scholar
- Kalinichenko VV, Bhattacharyya D, Zhou Y, Gusarove GA, Kim W, Shin B, Costa RH: Foxf1 +/- mice exhibit defective stellate cell activation and abnormal liver regeneration following CCl4 injury. Hepatology. 2003, 37: 107-117. 10.1053/jhep.2003.50005.View ArticlePubMedGoogle Scholar
- Knittel T, Kobold D, Saile B, Grundmann A, Neubauer K, Piscaglia F, Ramadori G: Rat liver myofibroblasts and hepatic stellate cells: different cell populations of the fibroblast lineage with fibrogenic potential. Gastroenterology. 1999, 117: 1205-1221. 10.1016/S0016-5085(99)70407-5.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.